Silent attacks in NMOSD: new study aims to predict disability before it strikes
NCT ID NCT07526298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 50 people with neuromyelitis optica spectrum disorder (NMOSD) who seem stable on rituximab treatment. Researchers want to see if hidden damage to brain cells, measured by a protein called GFAP and special MRI scans, can predict future relapses or worsening disability. Participants will be followed for 12 months with regular check-ups, blood tests, and MRI scans to catch any silent disease activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
San Raffaele Hospital
Milan, Milan, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study hopes to find a simple test for MS diagnosis
- Massive italian MS registry aims to unlock secrets of the disease
- New shot aims to stop devastating NMOSD Flare-Ups
- Could a zappy headband cure insomnia in MS patients?
- New drug aims to stop relapses in rare brain disease
- Engineered immune cells take aim at multiple sclerosis and myasthenia gravis